• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities

    7/10/26 7:25:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email

    NETANYA, Israel, July 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced that its wholly owned subsidiary Zorronet has completed the transition of its core operations to a new data center.

    The new data center is designed to improve response times and cost efficiency, and to increase capacity for handling complex security events in real time. The new data center forms a key part of Zorronet’s infrastructure modernization and supports its business expansion.

    "Completing the transition to a new advanced data center is an important milestone," said Idan Wasserman, CEO of Zorronet. "It improves our platform’s performance, scalability, and cost efficiency, allowing us to provide stronger real-time AI command-and-control solutions to our defense, homeland security, and critical infrastructure customers."

    Zorronet’s AI-powered command-and-control platform integrates video analytics, drones, sensors, and IoT devices into a unified operational intelligence environment. The new data center supports real-time threat detection, classification, prioritization, and automated response capabilities across mission-critical deployments.

    About BiomX

    BiomX Inc. is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company’s portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

    About Zorronet

    Zorronet Ltd., a BiomX company, develops command-and-control software that helps security and operations teams turn cameras, sensors, drones, and IoT devices into a unified real-time operating picture. The system, which is used in hundreds of sites, uses artificial intelligence and machine learning to detect, classify, and prioritize events, incidents, and potential threats, helping teams understand what is happening and coordinate faster responses. Designed for both defense and civilian security applications, Zorronet's systems are currently used in military sites, critical infrastructure, municipalities, smart cities, industrial facilities, large public venues, and more. By converting large volumes of sensor and system data into clear alerts and recommended actions, Zorronet has been enabling operators to manage and respond to complex activity and threats while reducing false alarms across everything from individual facilities to national borders.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as "expects," "intends," "plans," "believes," "will," "may," "anticipates," "estimates" and similar expressions, and include statements regarding the expected benefits, performance, scalability, and cost efficiency of Zorronet’s new data center; Zorronet’s continued business expansion and infrastructure modernization; the Company’s plan to regain compliance with the NYSE American continued listing standards, the actions the Company intends to take under the plan, and the Company’s ability to maintain the listing of its common stock on the NYSE American. These statements are based on the Company’s current expectations and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, the risk that the Company may not regain compliance with the NYSE American continued listing standards within the plan period or at all; the risk that the Company may not make progress consistent with its plan; the possibility that the Company’s common stock may be suspended from trading or delisted from the NYSE American; the Company’s ability to raise additional capital and to execute its business and strategic initiatives; the Company’s going concern qualification; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 19, 2026, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 20, 2026, as well as the Company’s other filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

    Contact

    Yair Ohayon

    Yairo@biomx.com



    Primary Logo

    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    SEC Filings

    View All

    SEC Form PRE 14A filed by BiomX Inc.

    PRE 14A - BiomX Inc. (0001739174) (Filer)

    7/17/26 5:00:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by BiomX Inc.

    EFFECT - BiomX Inc. (0001739174) (Filer)

    7/15/26 12:15:16 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by BiomX Inc.

    424B3 - BiomX Inc. (0001739174) (Filer)

    7/14/26 5:10:29 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Yeganeh Reuven sold $3,350,000 worth of shares (670,000 units at $5.00) and converted options into 670,000 shares (SEC Form 4)

    4 - BiomX Inc. (0001739174) (Issuer)

    3/13/26 4:30:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bidas Liat Cohavi

    3 - BiomX Inc. (0001739174) (Issuer)

    3/3/26 9:27:51 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities

    NETANYA, Israel, July 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced that its wholly owned subsidiary Zorronet has completed the transition of its core operations to a new data center. The new data center is designed to improve response times and cost efficiency, and to increase capacity for handling complex security events in real time. The new data center forms a key part of Zorronet’s infrastructure modernization and supports its business expansion. "Completing the transition to a new advanced data center is an important milestone," said Idan Wasserman, CE

    7/10/26 7:25:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities

    NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on acquiring and further developing technologies that identify, analyze, protect against and support faster responses to physical threats, today announced that its wholly owned subsidiary BiomX Israel Defense and Security Ltd. has signed a non-binding letter of intent (the "LOI") to acquire a 60% controlling interest in Tsoock Defense Technologies Ltd. ("Tsoock"), an Israeli security infrastructure and systems integration company with approximately 20 years of operating experience. The LOI is non-binding with respect to the proposed transaction terms, and there can be no

    7/8/26 7:05:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement

    NETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), announced today following its April 16, 2026 announcement that its wholly-owned subsidiary Zorronet has commenced supply and installation of its AI and ML-powered detection and command-and-control systems on sections of the Israel Railways network, in accordance with the framework supply agreement, focused on protecting wildlife and safeguarding national infrastructure. Zorronet provides and installs AI, ML and business intelligence-enabled alert stations capable of detecting and deterring animals and humans, including ongoing maintenance and 24/7 service center operations. The initial ph

    7/6/26 8:32:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Provides Update on Defense Technology Portfolio and Growth Strategy

    NETANYA, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), a company that develops and acquires technologies for defense, security, and first-response markets, today announced that it has posted an updated informational presentation to the Company's website as part of its completed strategic transition towards the defense sector. The presentation provides an overview of BiomX's portfolio, operating framework, leadership and advisory team, and growth strategy. BiomX's current strategy is built around the growing need for technologies that can identify, analyze, and support faster responses to physical threats across high-consequence settings. The Company's portfolio current

    6/18/26 9:15:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

    NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

    4/10/26 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care